$AXSM news
The latest AXSM stock news: headlines, filings, AI summaries and sentiment for $AXSM, updated around the clock.
- Xenon Pharmaceuticals Reports Q3 2026 Financial Results and Azetukalner FDA Submission
- Xeris Biopharma Reports Q3 2026 Revenue Growth Driven by Recorlev
- Harmony Biosciences Reports Q3 2026 Net Product Revenue of $268.9 Million Driven by WAKIX Growth
- Axsome Therapeutics Reports 52% Revenue Growth Driven by Auvelity Sales
- Jazz Pharmaceuticals Reports Q3 2026 Results with Revenue Growth and Raised Guidance
- Axsome Therapeutics, Inc. - 10-Q Filing
- Axsome Therapeutics Reports $260 Million in Q3 Revenue and Projects AUVELITY Peak Sales of $8 Billion
- Axsome Therapeutics Reports Strong Q3 2026 Results Driven by AUVELITY Growth
- Axsome Therapeutics Reports Q3 Revenue Beat and Improved EPS
- Axsome Therapeutics, Inc. - 8-K Filing
- Axsome Therapeutics Scheduled to Report Q3 2026 Earnings
- Axsome Therapeutics Shows Consistent Revenue Growth Amidst Moderna's Volatility
- Axsome Therapeutics Expands Auvelity into Alzheimer's Market with Strong Early Sales
- Axsome Therapeutics Reports Strong Revenue Growth and Pipeline Progress
- Axsome Reports Accelerated AUVELITY Prescriptions as Alzheimer’s Launch Progresses
- Axsome Therapeutics, Inc. - 8-K Filing
- Axsome Therapeutics, Inc. - 8-K Filing
- Axsome Therapeutics Stock Surges on FDA Approval and Positive Earnings Report
- Axsome Therapeutics Reports Q1 2026 Earnings
- Axsome Therapeutics Reports Q1 2025 Earnings with Strong Revenue Growth
- Axsome Therapeutics (AXSM) Q2 2025 Earnings Call Transcript
- Axsome Therapeutics (AXSM) Reports Q1 2026 Earnings with Strong Revenue Growth and FDA Approval for AUVELITY
- Axsome Therapeutics Reports Q1 2025 Earnings with Strong Revenue Growth
- Axsome Therapeutics Reports Strong Q2 2025 Earnings with Revenue Growth
- Axsome Therapeutics Reports Q1 Revenue Growth of 57% YoY and FDA Approval for Auvelity in Alzheimer's Agitation
- Stocks Making Significant Premarket Moves: eBay, Norwegian Cruise Line, Coinbase Among Others
- Axsome Therapeutics Stock Surges Over 20% Following FDA Approval Expansion
- Axsome Therapeutics Stock Rises Over 20% in April Due to FDA Approval for New Indication